<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040699</url>
  </required_header>
  <id_info>
    <org_study_id>KN046-IST-02</org_study_id>
    <nct_id>NCT04040699</nct_id>
  </id_info>
  <brief_title>KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor</brief_title>
  <official_title>A Phase Ib Study to Evaluate Efficacy, Safety and Tolerability of KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib, open-label, dose-escalation and expansion study to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and anti-tumor activity of KN026 combined with KN046 in&#xD;
      subjects with advanced HER2 positive solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is composed of 2 stages. Stage 1 consists of dose escalation cohorts for&#xD;
      determining the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2&#xD;
      consists of 4 tumor type expansion cohorts for expanding the information on clinical safety,&#xD;
      clinical pharmacokinetics and antitumor activity in HER2 positive patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity（DLT）</measure>
    <time_frame>28 days</time_frame>
    <description>Dose-limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate (ORR) per RECIST 1.1 criteria according to investigators assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Duration of response (DOR) per RECIST 1.1 criteria according to investigators assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Clinical benefit rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rates</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Progression free survival (PFS) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rates</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Overall survival (OS) rates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HER2 Positive Solid Tumor</condition>
  <arm_group>
    <arm_group_label>KN026 combined with KN046</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.&#xD;
KN046 is a PD-L1 - CTLA-4 bispecific antibody.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KN026 combined with KN046</intervention_name>
    <description>KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.</description>
    <arm_group_label>KN026 combined with KN046</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed inform consent form (ICF)&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 75 years, male or female&#xD;
&#xD;
          -  Histologically or cytologically documented advanced HER2 positive solid tumor&#xD;
&#xD;
          -  Received at least one prior standard therapy&#xD;
&#xD;
          -  At least one measurable lesion according to Response Evaluation Criteria In Solid&#xD;
             Tumors（RECISIT） v 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  LVEF≥ 50% (ECHO)&#xD;
&#xD;
          -  Female patients and males with partners of childbearing potential should be using&#xD;
             highly effective contraceptive measures (failure rate of less than 1% per year).&#xD;
             Contraception should be continued for a period of 24 weeks after dosing has been&#xD;
             completed.&#xD;
&#xD;
          -  Ability to comply with treatment, procedures and pharmacokinetics (PK) sample&#xD;
             collection and the required study follow-up procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Accepted any other anti-tumor drug therapies within 4 weeks before fist dose&#xD;
&#xD;
          -  Accepted radiotherapy within 4 weeks before enrollment&#xD;
&#xD;
          -  An anthracyclines antibiotic treatment was received exceeding 320 mg/m² or other&#xD;
             equivalent dose antharcyclines&#xD;
&#xD;
          -  Subjects are eligible with clinically controlled and stable neurologic function &gt;= 4&#xD;
             weeks, which is no evidence of CNS disease progression; Subjects with spinal cord&#xD;
             compression and cancerous meningitis are not eligible&#xD;
&#xD;
          -  Subjects receiving immunosuppressive agents (such as steroids) for any reason should&#xD;
             be tapered off these drugs before initiation of trial treatment (with the exception of&#xD;
             subjects with adrenal insufficiency, who may continue corticosteroids at physiologic&#xD;
             replacement doses, equivalent to &lt; 10 mg prednisone daily, inhaled steroids and&#xD;
             topical use of steroids)&#xD;
&#xD;
          -  Vaccination within 28 days of the first administration of trial treatment, except for&#xD;
             administration of inactivated vaccines (e.g., inactivated influenza vaccines)&#xD;
&#xD;
          -  Pregnant or nursing females；or intend pregnancy within this study period or within 6&#xD;
             monthes after the end of this study&#xD;
&#xD;
          -  Severe chronic and active infection, need to system antibiosis/antiviral treatment&#xD;
&#xD;
          -  Has interstitial lung disease, or a history of pneumonitis that required oral or&#xD;
             intravenous glucocorticoids to assist with management&#xD;
&#xD;
          -  Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well&#xD;
             controlled, and need locally treatment or repeated drainage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen, professor</last_name>
    <phone>86-10-88196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, Professor</last_name>
      <phone>010-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Lin Shen, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>MD,Professor,Chief of Department of GI Oncology,Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>KN026</keyword>
  <keyword>KN046</keyword>
  <keyword>HER2 Positive Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

